Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 18, 2005. The report details corporate actions regarding share repurchases and updates on directors' interests in company shares.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes via share buybacks.
- Share Repurchase (Feb 16, 2005): 800,000 shares purchased at 1,256.343 pence per share.
- Share Repurchase (Feb 18, 2005): 400,000 shares purchased at 1,238.1672 pence per share.
- Treasury Shares (Post-Feb 18): 73,133,000 shares held in Treasury.
- Shares in Issue (Post-Feb 18): 5,866,133,338 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through two separate buyback transactions executed on February 16 and February 18, 2005, authorized by shareholders at the May 17, 2004 Annual General Meeting. Additionally, the GlaxoSmithKline Employee Trust transferred 9,393 shares to participants in employee share plans on February 17, 2005.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the February 16 and February 18 share repurchases against cash flow statements in the next quarterly or annual report.
- Confirm the updated share count (5,866,133,338) in subsequent filings to ensure accuracy of the Treasury share calculation.
- Review the remaining authority for share buybacks granted at the May 2004 Annual General Meeting to assess future capital return potential.